Drugs / HR011408
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06375031 | May → Jul 2024 | diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05737576 | Mar → Oct 2023 | diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05147259 | Nov 2021 → Jan 2022 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HR011408 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05737576 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT05147259 ↗ |